Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1993-09-20
1995-01-31
Saunders, David
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 795, 436506, 436508, 436518, 436538, G01N 33537, G01N 33543, G01N 33564
Patent
active
053858247
DESCRIPTION:
BRIEF SUMMARY
The invention relates to a method for monitoring an autoimmune disease activity by detection and quantitative determination of anti-RNA antibodies in a test fluid of patients with an autoimmune disease and a test kit for carrying out the method.
BACKGROUND OF THE INVENTION
Since the discovery that sera of patients with systemic lupus erythematosus (SLE) contain antibodies to nuclear components, more refined methods have been developed to define the antigens involved in the reaction and to measure the concentration of antibody. Methods used to establish the nature of the antigen and antibody have included complement fixation, hemagglutination, precipitation of soluble immune complexes with ammonium sulfate, immunoprecipitation by double diffusion in agar and immunohistology. The reaction has been quantitated by dilution of the sera for immunohistology, by the extent of binding of DNA by the sera, and by solid phase radio immunoassay. The use of antibodies coupled to enzymes has opened the possibility of using such conjugates to replace the radioactive label in immunoassay systems.
Pesce et al (Clinical Chem. 20/3, 353-359, 1974) described a technique consisting of preparing an antigen on an insoluble support, layering the test serum with anti-DNA, and using this serum as an antigen to react with an anti-human IgG labeled with enzyme-peroxidase. In principle, the amount of IgG bound to the insoluble support is proportional to the amount of antibody contained in the serum. Pesce et al demonstrated that a solid phase noncompetitive binding assay, with use of a second antibody conjugated to an enzyme as the quantitive or detector system, is a valid way to measure antibody to DNA in serum.
Patients with systemic autoimmune diseases produce a variety of antibodies directed against normal cellular components. Several well characterized autoantibody systems are directed against specific proteins or nucleic acid-protein complexes (Tan, E. M (1989) Adv. Immunol. 44, 93-151). Sera from patients with connective tissue diseases often contain antibodies against cellular components consisting of proteins associated with small RNA molecules of 80-200 nucleotides in length. Autoantibodies against the nuclear type of these small RNA-protein complexes (snRNP) are mostly found in sera from patients with SLE or SLE overlap syndromes. Several specificities have already been described. There are antibodies that precipitate (U1)snRNP only, due to the fact that they recognise one or more of the (U1)snRNP specific proteins viz. 70K, A and C. Another specificity, anti-Sm, precipitates all the major nucleoplasmic snRNPS due to the fact that these antibodies recognise the proteins B'/B and D which are common to these snRNPS (v. Venrooij and Sillekens, Clin. Exp. Rheum., 1989).
The antibodies in the patients sera are in all these cases directed against proteins contained in the snRNP complexes. Although nucleic acids are generally poor immunogens, autoantibodies directed against nucleic acids have been reported. The majority of studies of nucleic acid antibodies have concerned anti-DNA activities, although examples of anti-viral RNA autoantibodies have been described.
Antibodies against the (U)RNA components of snRNP are thought to be rare (Tan, 1989). Wilusz and Keene described in 1986 (J. Biol. Chem, 261, 5467-5472) the presence of anti-(U1)RNA autoantibodies in two anti-RNP sera. From this article no general conclusions regarding an association between anti-RNP and/or Sm activity and anti-(U1)RNA activity could be drawn. Deutscher and Keene described in 1988 (P.N.A.S., 85, 3299-3303) that the part of the (U1)RNA recognised by one of said sera was mapped and found to include the second stem-loop of the RNA.
We initiated a study in which a large number of anti-snRNP sera were tested for the presence of anti(U1)RNA antibodies. Via screening with CIE (counter immuno-electrophoresis) and IB (immunoblotting), 118 sera containing anti-snRNP activity were identified. Following RNP immunoprecipitation sixty sera were classified as anti-(U1
REFERENCES:
patent: 4784942 (1988-11-01), Harley
D. Eliat et al, Jour. Immunol., 120, 550-557, 1978.
Gioud et al., "Etude des anticorps antihistones et anti-ARN bicatenaires dans les connectivites par une technique immunoenzymatique," Revue Du Rhumatisme, vol. 49, No. 5, pp. 385-391, Apr. 1982, Paris, France.
Adamashvili et al., "Antibodies to nucleic acids in systemic lupus erythematosus and rheumatoid arthritis patients and their relatives," Immunology Letters, vol. 6, pp. 33-38, 1983.
Deutscher et al., "A sequence-specific conformational epitope on U1 RNA is recognized by a unique autoantibody,"Proceedings of the National Academy of Sciences, vol. 85, No. 10, pp. 3299-3303, May 1988, USA.
Wilusz et al., "Autoantibodies specific for U1 RNA and initiatior methionine tRNA,"The Journal of Biological Chemistry, vol. 261, No. 12, pp. 5467-5472, Apr. 25, 1986, USA.
Pesce et al., "Use of enzyme-linked antibodies to measure serum anti-DNA antibody in systemic lupus erythematosus," Clinical Chemistry, vol. 20, No. 3, pp. 353-359, Mar. 1974.
Hoet Rene M. A.
Van Venrooy Waltherus J.
Akzo N.V.
Blackstone William M.
Saunders David
LandOfFree
Method for detection of anti-RNA-antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for detection of anti-RNA-antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for detection of anti-RNA-antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1101703